Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced the pricing of an underwritten registered offering of 15,790,000 shares of its common stock, par value US$0.001 per share, offered at a price of US$28.50 per share, before underwriting discounts. The offering is expected to close on or about January 5, 2024, subject to customary closing conditions. Gross offering proceeds will be approximately US$450.0 million, before deducting underwriting discounts and commissions and estimated offering expenses.
Latham & Watkins LLP represents the underwriters in the offering, with a capital markets team led by San Diego partner Matt Bush and counsel Anthony Gostanian, with associates Peter Simon, Brian Daley, and Sterling Swift.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.